These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22682136)

  • 1. Transfusion issues in cancer patients.
    Federici AB; Vanelli C; Arrigoni L
    Thromb Res; 2012 Apr; 129 Suppl 1():S60-5. PubMed ID: 22682136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis.
    Federici AB; Intini D; Lattuada A; Vanelli C; Arrigoni L; Sacchi E; Russo U
    Thromb Res; 2014 May; 133 Suppl 2():S56-62. PubMed ID: 24862147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer.
    Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G
    Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of blood transfusion and their prevention.
    Sandler SG; Yu H; Rassai N
    Clin Adv Hematol Oncol; 2003 May; 1(5):307-13. PubMed ID: 16224428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease.
    Papay P; Hackner K; Vogelsang H; Novacek G; Primas C; Reinisch W; Eser A; Mikulits A; Mayr WR; Körmöczi GF
    Am J Med; 2012 Jul; 125(7):717.e1-8. PubMed ID: 22560809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current risks in blood transfusion in Japan.
    Otsubo H; Yamaguchi K
    Jpn J Infect Dis; 2008 Nov; 61(6):427-33. PubMed ID: 19050347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advancement in the preparation of red cell concentrates and platelet concentrates].
    Inaba S
    Masui; 2011 Jan; 60(1):23-30. PubMed ID: 21348247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Cox JV; Steane E; Cunningham G; Frenkel EP
    Arch Intern Med; 1988 Nov; 148(11):2485-9. PubMed ID: 3142382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk of immunization to blood cells and diagnostic and therapeutic implications].
    Kiefel V
    Beitr Infusionsther; 1993; 31():44-51. PubMed ID: 7693263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A program to limit donor exposures to neonates undergoing extracorporeal membrane oxygenation.
    Rosenberg EM; Chambers LA; Gunter JM; Good JA
    Pediatrics; 1994 Sep; 94(3):341-6. PubMed ID: 8065860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of platelets in transfusion medicine.
    Brubaker DB
    J Am Osteopath Assoc; 1989 Dec; 89(12):1553-9. PubMed ID: 2621122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anesthesiology update #19. Adverse reactions to transfusion.
    Stehling LC
    Orthop Rev; 1986 Nov; 15(11):736-40. PubMed ID: 3453918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Treleaven J
    Bone Marrow Transplant; 1996 Jul; 18(1):151-6. PubMed ID: 8832008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusion and alternatives to transfusion in patients with malignancy.
    Vaickus L; Breitmeyer JB; Schlossman RL; Anderson KC
    Stem Cells; 1995 Nov; 13(6):588-96. PubMed ID: 8590860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underreporting of minor transfusion reactions in cancer patients.
    Narvios AB; Lichtiger B; Neumann JL
    MedGenMed; 2004 May; 6(2):17. PubMed ID: 15266243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.
    Webb IJ; Soiffer RJ; Andersen JW; Cohen CA; Freeman A; Sugrue M; Ritz J; Anderson KC
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):267-72. PubMed ID: 9450922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role and impact of the transfusion medicine consultation service in the management of patients in the hematopoietic transplant service: A retrospective analysis.
    Narvios A; Rodriguez-Jackson L; Reddy V; Lichtiger B
    Transfus Clin Biol; 2009 Sep; 16(4):383-7. PubMed ID: 19665413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte-reduced blood components: patient benefits and practical applications.
    Higgins VL
    Oncol Nurs Forum; 1996 May; 23(4):659-67. PubMed ID: 8735324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.